Mustang Bio Files 8-K on Shareholder Vote Matters

TL;DR

Mustang Bio held a shareholder vote, details to follow.

AI Summary

Mustang Bio, Inc. filed an 8-K on January 10, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain details about the specific proposals voted upon or the outcome of the vote.

Why It Matters

This filing indicates that Mustang Bio held a shareholder vote, which could pertain to significant corporate actions or governance changes that may impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial information or material events that would immediately impact the company's risk profile.

Key Players & Entities

• Mustang Bio, Inc. (company) — Registrant
• January 10, 2025 (date) — Filing Date
• Delaware (jurisdiction) — State of Incorporation
• Worcester, Massachusetts (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share MBIO Nasdaq Capital Marke

Filing Documents

• tm252981d1_8k.htm (8-K) — 25KB
• 0001104659-25-002599.txt ( ) — 192KB
• mbio-20250110.xsd (EX-101.SCH) — 3KB
• mbio-20250110_lab.xml (EX-101.LAB) — 33KB
• mbio-20250110_pre.xml (EX-101.PRE) — 22KB
• tm252981d1_8k_htm.xml (XML) — 3KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. Effective January 10, 2025, the holders of a majority of the voting power of the capital stock of Mustang Bio, Inc. (the "Company") executed a written consent authorizing, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of up to an aggregate of 34,767,934 shares of the Company's common stock underlining certain outstanding warrants issued by the Company pursuant to (A) that certain previously disclosed Investor Inducement Letter Agreement, dated as of October 24, 2024 (the "Inducement Letter"), with a certain institutional investor (the "Investor"), and (B) that certain previously disclosed engagement letter, dated as of October 23, 2024 (the "Engagement Letter'), with H.C. Wainwright & Co., LLC (the "Placement Agent"), in an amount equal to or in excess of 20% of the number of shares of common stock outstanding immediately prior to the issuance of such warrants (collectively, the "Warrant Share Issuance"). The written consent was signed by the holders of 6,552,781 shares of the Company's issued and outstanding common stock and 250,000 shares of the Company's issued and outstanding ClassA Preferred Stock. Each share of common stock and ClassA Common Stock entitles the holder thereof to one vote on all matters submitted to stockholders and each share of Class A Preferred Stock has the voting power of 1.1 times (A) the number of outstanding shares of common stock plus (B) the whole shares of common stock into which the outstanding shares of ClassA Common Stock and ClassA Preferred Stock are convertible, divided by the number of outstanding shares of Class A Preferred Stock, or 285 votes per share as of January 10, 2025. Accordingly, the holders of approximately 57% of the voting power of the Company's capital stock as of January 10, 2025 signed the written consent approving the Warrant Share Issuance. Pursuant to rules adopted by the Securities and Exchange Commission under th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mustang Bio, Inc. (Registrant) Date: January 10, 2025 By: /s/ Manuel Litchman, M.D. Name: Manuel Litchman, M.D. Title: President, Chief Executive Officer and Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR